United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

21 Feb 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)


Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --


  ALNY.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -5.12 -- --
ROI: -33.58 8.92 14.45
ROE: -39.86 10.08 15.96

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

Sep 27 2018

UPDATE 4-Early approval of Alnylam's gene-silencing drug in question

* Co still plans to discuss potential early approval with FDA

Sep 27 2018

Earnings vs. Estimates